RefleXion's Chief Business Officer, Thorsten Melcher Ph.D., and Chris Behrenbruch Ph.D, founder and CEO of Telix Pharmaceuticals, explore how holistic treatment strategies for metastatic cancer patients interact with the world of commerce. What is the role of radiopharmacueticals in the radiotherapy delivery? What influence does the design of clinical trials have on market authorization? Why would a company deliberately integrate with an existing therapy rather than replace it? Find out in this forward-looking discussion.

Speakers:
Thorsten Melcher Ph.D. - CBO, RefleXion
Chris Behrenbruch Ph.D, - Founder and CEO, Telix Pharmaceuticals

For more information, please visit https://reflexion.com